The price of Humalog has surged to more than $250 per vial from $21 a vial over the past 20 years, according to the Washington Post. The treatment generated $640.8 million in third-quarter revenue for Eli Lilly.

Drug makers such as Eli Lilly have come under fire recently for drastically hiking the price of certain treatments.

Separately, TheStreet Ratings team rates the stock as a "buy" with a ratings score of B+.

Eli Lilly's strengths such as its revenue growth and expanding profit margins outweigh the fact that the company has had lackluster performance in the stock itself.

TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this article's author.